WO2009137872A1 - Méthodes et compositions permettant le traitement du cancer - Google Patents

Méthodes et compositions permettant le traitement du cancer Download PDF

Info

Publication number
WO2009137872A1
WO2009137872A1 PCT/AU2009/000592 AU2009000592W WO2009137872A1 WO 2009137872 A1 WO2009137872 A1 WO 2009137872A1 AU 2009000592 W AU2009000592 W AU 2009000592W WO 2009137872 A1 WO2009137872 A1 WO 2009137872A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
fusion region
region comprises
vector according
vector
Prior art date
Application number
PCT/AU2009/000592
Other languages
English (en)
Inventor
Gregory John Allen
Original Assignee
Simons Haplomics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simons Haplomics Limited filed Critical Simons Haplomics Limited
Priority to US12/992,620 priority Critical patent/US20110071214A1/en
Priority to CA2760041A priority patent/CA2760041A1/fr
Publication of WO2009137872A1 publication Critical patent/WO2009137872A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des compositions et des méthodes permettant le traitement du cancer, et est basée au moins en partie sur l'utilisation de régions de fusion de gènes comme cibles thérapeutiques.  La cible des régions de fusion peut être physiquement matérialisée au niveau d'un ADN, un ARN ou une protéine. Généralement, la région de fusion est spécifique à des cellules cancéreuses ou pré-cancéreuses, ce qui signifie que toute thérapie dirigée vers la cible peut ne pas agir de façon significative sur un tissu non cancéreux. La région de fusion peut être ciblée par des molécules de protéine ou d'acide nucléique pouvant se lier de façon spécifique à la région.
PCT/AU2009/000592 2008-05-14 2009-05-13 Méthodes et compositions permettant le traitement du cancer WO2009137872A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/992,620 US20110071214A1 (en) 2008-05-14 2009-05-13 Methods and compositions for the treatment of cancer
CA2760041A CA2760041A1 (fr) 2008-05-14 2009-05-13 Methodes et compositions permettant le traitement du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7171208P 2008-05-14 2008-05-14
US61/071,712 2008-05-14

Publications (1)

Publication Number Publication Date
WO2009137872A1 true WO2009137872A1 (fr) 2009-11-19

Family

ID=41318278

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2009/000592 WO2009137872A1 (fr) 2008-05-14 2009-05-13 Méthodes et compositions permettant le traitement du cancer

Country Status (3)

Country Link
US (1) US20110071214A1 (fr)
CA (1) CA2760041A1 (fr)
WO (1) WO2009137872A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020127487A1 (fr) 2018-12-21 2020-06-25 Aarhus Universitet Thérapie génique par crispr de cancers liés au gène de fusion

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11154597B2 (en) * 2016-03-24 2021-10-26 Nantcell, Inc. Sequence arrangements and sequences for neoepitope presentation
WO2017189959A1 (fr) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448987A4 (fr) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
CA3061240C (fr) 2017-04-24 2024-01-16 Nantcell, Inc. Vecteurs de neo-epitopes cibles et procedes associes
AU2018346511A1 (en) * 2017-10-05 2020-04-23 Nantcell, Inc. Multivalent antigens stimulating Th1 and Th2
US20200354730A1 (en) * 2017-11-27 2020-11-12 Nantcell, Inc. Improved Yeast Polytope Vaccine Compositions And Methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006166A1 (fr) * 1994-08-20 1996-02-29 Medical Research Council Ameliorations concernant des proteines de liaison permettant de reconnaitre l'adn
WO1997046672A2 (fr) * 1996-06-05 1997-12-11 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Acides nucleiques antisens et ribozymes a tete de marteau
US20050119185A1 (en) * 2003-12-01 2005-06-02 David Scheinberg Synthetic HLA binding peptide analogues and uses thereof
WO2006073602A2 (fr) * 2004-11-24 2006-07-13 Alnylam Pharmaceuticals, Inc. Modulation arni du gene de fusion bcr-abl et applications associees

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006166A1 (fr) * 1994-08-20 1996-02-29 Medical Research Council Ameliorations concernant des proteines de liaison permettant de reconnaitre l'adn
WO1997046672A2 (fr) * 1996-06-05 1997-12-11 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Acides nucleiques antisens et ribozymes a tete de marteau
US20050119185A1 (en) * 2003-12-01 2005-06-02 David Scheinberg Synthetic HLA binding peptide analogues and uses thereof
WO2006073602A2 (fr) * 2004-11-24 2006-07-13 Alnylam Pharmaceuticals, Inc. Modulation arni du gene de fusion bcr-abl et applications associees

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CATHCART, K. ET AL.: "A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia", BLOOD, vol. 103, no. 3, 2004, pages 1037 - 1042 *
KESSLER, J.H. ET AL.: "BCR-ABL fusion regions as a source of multiple leukemia- specific CD8+ T-cell epitopes", LEUKEMIA, vol. 20, 2006, pages 1738 - 1750 *
SUN, J.-Y. ET AL.: "Immunogenicity of a p210BCR-ABL fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro", CANCER RESEARCH, vol. 62, 2002, pages 3175 - 3183 *
ZHAO, R.C.H. ET AL.: "Gene therapy for chronic myelogenous leukemia (CML): A retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo", BLOOD, vol. 90, no. 12, 1997, pages 4687 - 4698 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020127487A1 (fr) 2018-12-21 2020-06-25 Aarhus Universitet Thérapie génique par crispr de cancers liés au gène de fusion

Also Published As

Publication number Publication date
US20110071214A1 (en) 2011-03-24
CA2760041A1 (fr) 2009-11-19

Similar Documents

Publication Publication Date Title
US20110071214A1 (en) Methods and compositions for the treatment of cancer
US11110180B2 (en) Nucleic acid-polypeptide compositions and uses thereof
JP6523224B2 (ja) 組換えベクター
CN110760007B (zh) Cd7-car-t细胞及其制备和应用
CN108018299B (zh) 靶向bcma的嵌合抗原受体及其用途
JP6682509B2 (ja) キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
US20190000987A1 (en) Nucleic acid-polypeptide compositions and uses thereof
DK2066795T3 (en) PSEUDOTYPING OF RETROVIRUS VECTORS, PROCEDURES FOR PREPARING AND USING THEREOF FOR TARGETED TRANSMISSION AND HIGH SCREENING SCREENING
CN109593721B (zh) 具有自杀基因开关的靶向人间皮素的工程化免疫细胞
US11413341B2 (en) Vaccinia viral vectors encoding chimeric virus like particles
JP2009100782A (ja) 治療および診断に使用する新規な特性をもたらしおよび／または該特性を現す組成物
WO2019154204A1 (fr) Vecteur d'ingénierie génique de récepteur d'antigène chimère, cellule immune modifiée ainsi et son application
JP2009508516A (ja) 核酸構築物、薬剤組成物、及び癌治療のためのその使用方法
EP2997148B1 (fr) Bactériophage
JP2022529380A (ja) キメラ抗原受容体構築物およびｃａｒ－ｔ細胞におけるそれらの使用
CN108342360A (zh) 共表达抗msln嵌合抗原受体和无功能egfr的转基因淋巴细胞及其用途
WO2009095500A1 (fr) Inhibiteurs de la réplication lentivirale
CN110526987A (zh) 靶向cd133的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
CN112368007A (zh) 抗原隐匿的溶瘤病毒
EP1521839B1 (fr) Methodes permettant d'obtenir des particules presentant une activite de liaison cellulaire modifiee et utilisations correspondantes
JP2020099326A (ja) キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
CN112876566A (zh) 一种cd3特异性慢病毒的构建及其应用
EP4357369A1 (fr) Préparation et utilisation d'une cellule immunitaire de récepteur antigénique chimérique construite sur la base de granzyme b
US11970708B2 (en) Gene therapy vector with minimizing recombination, recombinant retrovirus comprising the vector, and pharmaceutical composition for preventing or treating cancer comprising the recombinant retrovirus
WO2024059791A1 (fr) Grandes recombinases de sérine, systèmes et utilisations de celles-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09745294

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12992620

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 02/03/2011)

122 Ep: pct application non-entry in european phase

Ref document number: 09745294

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2760041

Country of ref document: CA